Specgx LLC

Specgx LLC, doing business as Mallinckrodt Pharmaceuticals, is a foreign-owned pharmaceutical manufacturer that supplies controlled substance medications and specialized drugs to the federal government as a prime contractor, operating without set-aside designations across full-and-open competitive procurements and single-award indefinite delivery vehicles with the Defense Logistics Agency and the Department of Veterans Affairs.

Specgx manufactures pharmaceutical products at facilities in Webster Groves, Missouri (headquarters) and Hobart, New York. The vendor's federal portfolio concentrates on manufacturing and distributing controlled substances — methadone, morphine, hydrocodone-acetaminophen, methylphenidate, atropine/diphenoxylate, and buprenorphine/naloxone formulations — under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6515 (Drugs and Biologicals). The company competes exclusively as a prime contractor with no subcontract footprint.

Customer concentration tilts heavily toward the Department of Veterans Affairs and the Defense Logistics Agency (DLA). VISN 5 (Veterans Integrated Service Network 5) accounts for 23 awards with $107 thousand combined potential value — nearly all delivery orders under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) for methadone formulations supporting VA substance abuse treatment programs, ranging from $3,747.20 to $5,572.44 per order. However, dollar concentration inverts at the top: VISN 12 holds 2 awards totaling $706.1 million in combined potential value, while DLA Troop Support Medical anchors 9 awards with $109.4 million. The Drug Enforcement Administration accounts for 4 awards ($1 thousand combined potential value) for oxycodone and reference-material placebo tablets used in DEA laboratory operations and reverse undercover investigations. These five customers represent 93% of award count and 100% of combined potential value.

Specgx holds six single-award indefinite delivery contracts with DLA Troop Support Medical and one single-award contract with the National Acquisition Center (GSA). The DLA vehicles span morphine immediate-release and extended-release tablets ($2.2 million ceiling through November 2030), hydrocodone-acetaminophen tablets ($29.3 million ceiling through February 2030), methylphenidate HCL extended-release tablets ($4.2 million ceiling through December 2029), methylphenidate HCL immediate-release tablets ($5.9 million ceiling through September 2029), and a general pharmaceutical manufacturing/distributor IDV ($7.3 million ceiling through September 2027). The National Acquisition Center contract covers atropine/diphenoxylate HCL tablets ($1.4 million ceiling through May 2027). Specgx also holds a multi-agency GSA Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) with a $376 million ceiling through September 2027, though the source notes a $107.6 million figure in narrative descriptions of the VA's underlying vehicle; the FSS-61-IB generates 17 delivery orders valued at $117 thousand combined. Award velocity has slowed in recent years (eight awards in 2022, declining to two in 2026), but the DLA and VA single-award IDVs establish a multi-year, multi-agency supply pipeline for controlled substance medications to federal healthcare systems, corrections agencies, and law enforcement operations.